It’s been a crucial week for IntelliPharmaCeutics International Inc. (NASDAQ:IPCI); here’s what analysts have to say.

May 18, 2018 - By Marguerite Chambers

IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) Logo

IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) Ratings Coverage

Among 2 analysts covering IntelliPharmaCeutics Intl (NASDAQ:IPCI), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. IntelliPharmaCeutics Intl had 4 analyst reports since January 19, 2018 according to SRatingsIntel. The firm earned “Hold” rating on Friday, February 16 by Maxim Group. On Monday, March 5 the stock rating was maintained by H.C. Wainwright with “Buy”. H.C. Wainwright maintained the shares of IPCI in report on Monday, February 12 with “Buy” rating. Below is a list of IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) latest ratings and price target changes.

05/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $2.5 Maintain
16/02/2018 Broker: Maxim Group Rating: Hold Downgrade
12/02/2018 Broker: H.C. Wainwright Rating: Buy New Target: $2.5 Maintain
19/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $2.5 Initiates Coverage On

The stock decreased 0.23% or $0.001 during the last trading session, reaching $0.429. About 481,299 shares traded or 89.05% up from the average. IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) has declined 75.33% since May 18, 2017 and is downtrending. It has underperformed by 86.88% the S&P500.

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and makes novel and generic controlled-release and targeted-release oral solid dosage drugs in Canada. The company has market cap of $19.25 million. It develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. It currently has negative earnings. The companyÂ’s lead product is Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for attention deficit hyperactivity disorders.

More news for IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) were recently published by: Streetinsider.com, which released: “Intellipharmaceutics (IPCI) Receives Delisting Determination from NASDAQ Staff” on April 23, 2018. Seekingalpha.com‘s article titled: “FDA OKs first non-opioid treatment for opioid withdrawal” and published on May 16, 2018 is yet another important article.

IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.